Page last updated: 2024-09-04

jtt 501 and Disease Models, Animal

jtt 501 has been researched along with Disease Models, Animal in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chung, SS; Hu, W; Ko, BC; Li, Z; Liao, C; Lu, XP; Ning, ZQ; Pan, D; Shan, S; Shi, L; Tong, EH; Wong, VK; Yin, Z; Zhou, J	1
Matsui, K; Shibata, T; Wakitani, K; Yonemori, F	1

Other Studies

2 other study(ies) available for jtt 501 and Disease Models, Animal

Article	Year
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators. Bioorganic & medicinal chemistry letters, 2004, Jul-05, Volume: 14, Issue:13 Topics: Adipose Tissue; Administration, Oral; Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Hypolipidemic Agents; Ketones; Lipid Metabolism; Mice; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship	2004
JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models. British journal of pharmacology, 1998, Volume: 125, Issue:8 Topics: Animals; Blood Glucose; Disease Models, Animal; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Isoxazoles; Leptin; Lipids; Male; Obesity; Oxidation-Reduction; Phosphorylation; Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Triglycerides	1998

Article

Year

Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.

Bioorganic & medicinal chemistry letters, 2004, Jul-05, Volume: 14, Issue:13

Topics: Adipose Tissue; Administration, Oral; Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Hypolipidemic Agents; Ketones; Lipid Metabolism; Mice; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship

2004

JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.

British journal of pharmacology, 1998, Volume: 125, Issue:8

Topics: Animals; Blood Glucose; Disease Models, Animal; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Isoxazoles; Leptin; Lipids; Male; Obesity; Oxidation-Reduction; Phosphorylation; Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Triglycerides

1998